Sigma Planning Corp lifted its position in shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY – Free Report) by 369.1% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 70,363 shares of the company’s stock after buying an additional 55,363 shares during the quarter. Sigma Planning Corp’s holdings in Brainsway were worth $935,000 at the end of the most recent quarter.
A number of other institutional investors have also bought and sold shares of the business. Y.D. More Investments Ltd raised its holdings in Brainsway by 136.6% during the first quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company’s stock valued at $3,615,000 after acquiring an additional 157,042 shares during the period. ARK Investment Management LLC purchased a new position in shares of Brainsway in the fourth quarter valued at about $2,422,000. Two Sigma Investments LP boosted its stake in shares of Brainsway by 25.2% in the third quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock worth $1,551,000 after acquiring an additional 20,706 shares during the period. Legato Capital Management LLC boosted its stake in shares of Brainsway by 9.3% in the fourth quarter. Legato Capital Management LLC now owns 97,376 shares of the company’s stock worth $1,852,000 after acquiring an additional 8,295 shares during the period. Finally, Huntleigh Advisors Inc. grew its position in shares of Brainsway by 5.8% during the fourth quarter. Huntleigh Advisors Inc. now owns 87,076 shares of the company’s stock worth $1,656,000 after purchasing an additional 4,811 shares in the last quarter. Hedge funds and other institutional investors own 30.11% of the company’s stock.
Brainsway Stock Up 6.0%
BWAY opened at $15.73 on Friday. The company has a market capitalization of $631.24 million, a PE ratio of 44.94 and a beta of 1.22. The firm has a 50-day simple moving average of $15.01 and a two-hundred day simple moving average of $13.71. Brainsway Ltd. Sponsored ADR has a 52 week low of $5.68 and a 52 week high of $17.35.
Analysts Set New Price Targets
Several brokerages recently issued reports on BWAY. Wall Street Zen raised Brainsway from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Zacks Research upgraded Brainsway from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price objective on shares of Brainsway in a report on Friday. Finally, Weiss Ratings upgraded shares of Brainsway from a “hold (c)” rating to a “buy (b-)” rating in a research report on Friday, April 24th. One investment analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $14.50.
Get Our Latest Research Report on BWAY
Brainsway Profile
Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.
The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.
Recommended Stories
- Five stocks we like better than Brainsway
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Want to see what other hedge funds are holding BWAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY – Free Report).
Receive News & Ratings for Brainsway Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainsway and related companies with MarketBeat.com's FREE daily email newsletter.
